Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 ,inter alia, to consider and approve Approval of ....
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals has informed BSE and NSE that its Board of Directors will meet on Thursday, 6 November 2025. The agenda includes consideration and approval of unaudited financial results for the second quarter and half year ended 30 September 2025. This is a standard regulatory intimation under SEBI LODR Regulations 29 and 33. No financial numbers or material decisions have been disclosed in this filing — only the meeting date and agenda.
No immediate impact on shareholders. Investors should watch for the actual Q2/H1 FY26 results announcement on or after 6 November 2025 for any meaningful stock movement.